Access Clinical Trials DEA History 
Americans for Safe Access
JUNE 2, 2020
On March 23, DEA published a proposed rulemaking —“Controls to Enhance the Cultivation of Marihuana for Research in the United States”—in the Federal Register (85 FR 16292), involving who can grow cannabis in bulk for research purposes.
NORML
OCTOBER 21, 2019
Justices for the US Court of Appeals for the District of Columbia denied the petition following a filing by DEA in the Federal Register stating that the agency “intends to promulgate regulations” to review several dozen federal cultivation applications.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
SpeedWeed
MAY 15, 2021
A first-of-its-kind Phase 3 clinical trial has found that MDMA-assisted therapy provided meaningful relief from PTSD symptoms in nearly 90 percent of study participants. The subjects had been experiencing PTSD symptoms for an average of 14 years, and 84 percent had a history of developmental trauma. Image via.
Canna Law Blog
NOVEMBER 27, 2021
So according to the DEA, its abuse potential is high and it has no medical use. Also, according to the DEA, “the history of human experience probably goes back several hundred years since DMT usage is associated with a number of religious practices and rituals.”
Cannabis Law Report
JULY 9, 2021
Then, in November 2019, the FDA granted the designation to the nonprofit Usona Institute to study psilocybin’s effect on major depressive order, for which clinical trials are currently under way. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].
Cannabis Law Report
FEBRUARY 28, 2022
Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. Patents on psychedelics raise unique concerns associated with their unusual qualities, history, and regulation. Trial of Psilocybin Versus Escitalopram for Depression , 384 NEW ENG. Mitchell et al.,
SpeedWeed
MARCH 18, 2021
They also wrote: The study sample included participants with a history of cannabis use. Given the topical nature of the current trial and its relevance for public policy on medical cannabis, participants might have been biased to report positive effects regardless of condition. It tested at only 9% THC. Establishing cannabis as safe.
Expert insights. Personalized for you.
230 
Let's personalize your content